Fig. 56 (abstract P339).

Intratumoral injection of MVA∆E3L and MVA induces activating TILs in injected and non-injected tumors. B16-F10 melanoma cells were implanted intradermally to the left and right flanks of C57B/6 mice (5 x 10e5 to the right flank and 2.5 x 10e5 to the left flank). 7 days after tumor implantation, the larger tumors on the right flank were intratumorally injected with 2 x 10e7 pfu of MVA or an equivalent amount of MVAΔE3L, repeated three days later. Both injected and non-injected tumors were harvested at 3 days post the second injection, and TILs were analyzed by FACS. Shown here is a series of graphical representations of data showing that intratumoral injection of MVA or MVA∆E3L induces activated effector CD8+ and CD4+ T cells in both injected and non-injected tumors in a murine B16-F10 melanoma bilateral implantation model. (A) Dot-plots of flow cytometric analysis of CD8+ cells expressing granzyme B+. (B) %CD8+ granzyme B+ T cells in both injected and non-injected tumors treated with PBS, MVA or MVA∆E3L. (C) Dot-plots of flow cytometric analysis of CD4+ cells expressing granzyme B+. (D) %CD4+ granzyme B+ T cells in both injected and non-injected tumors treated with PBS, MVA or MVA∆E3L. (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001). (E) Histogram of CD8+ granzyme B+ and CD4+ granzyme B+ TILs in both injected and non-injected tumors treated with PBS, MVA or MVA∆E3L